Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctiontransferase activity, transferring phosphorus-containing groups

PRPS2 TRPM7 PPIP5K1 AXL FGFR2 CDS2

6.87e-04938246GO:0016772
GeneOntologyMolecularFunctionADP binding

PRPS2 MYO9B

1.51e-0348242GO:0043531
GeneOntologyMolecularFunctionkinase activity

PRPS2 TRPM7 PPIP5K1 AXL FGFR2

1.88e-03764245GO:0016301
GeneOntologyMolecularFunctiontransmembrane receptor protein tyrosine kinase activity

AXL FGFR2

2.75e-0365242GO:0004714
GeneOntologyMolecularFunctiontransmembrane signaling receptor activity

OR4K17 AXL TACR1 FGFR2 HTR1E MCHR2

4.47e-031353246GO:0004888
GeneOntologyMolecularFunctiontransmembrane receptor protein kinase activity

AXL FGFR2

4.65e-0385242GO:0019199
GeneOntologyMolecularFunctionmyosin binding

TRPM7 AXL

4.65e-0385242GO:0017022
DomainIRO

IRX2 IRX5

2.37e-056242SM00548
DomainIroquois_homeo

IRX2 IRX5

2.37e-056242IPR003893
DomainARM-type_fold

DIAPH2 MROH9 NBEAL1 NF1 ITPR1

6.12e-05339245IPR016024
DomainHomeobox_KN

IRX2 IRX5

2.13e-0417242PF05920
DomainHomeobox_KN_domain

IRX2 IRX5

2.13e-0417242IPR008422
DomainTyrKc

AXL FGFR2

5.66e-0388242SM00219
DomainTyr_kinase_cat_dom

AXL FGFR2

5.66e-0388242IPR020635
DomainRho_GTPase_activation_prot

MYO9B NF1

5.66e-0388242IPR008936
DomainPROTEIN_KINASE_TYR

AXL FGFR2

6.84e-0397242PS00109
DomainTyr_kinase_AS

AXL FGFR2

6.84e-0397242IPR008266
DomainIon_trans_dom

TRPM7 ITPR1

9.34e-03114242IPR005821
DomainIon_trans

TRPM7 ITPR1

9.34e-03114242PF00520
DomainGPCR_Rhodpsn_7TM

OR4K17 TACR1 HTR1E MCHR2

9.85e-03670244IPR017452
Domain7tm_1

OR4K17 TACR1 HTR1E MCHR2

1.02e-02677244PF00001
DomainG_PROTEIN_RECEP_F1_1

OR4K17 TACR1 HTR1E MCHR2

1.06e-02685244PS00237
DomainG_PROTEIN_RECEP_F1_2

OR4K17 TACR1 HTR1E MCHR2

1.09e-02691244PS50262
DomainGPCR_Rhodpsn

OR4K17 TACR1 HTR1E MCHR2

1.10e-02692244IPR000276
DomainPkinase_Tyr

AXL FGFR2

1.18e-02129242PF07714
DomainSer-Thr/Tyr_kinase_cat_dom

AXL FGFR2

1.34e-02138242IPR001245
Pubmed

CTDP1 regulates breast cancer survival and DNA repair through BRCT-specific interactions with FANCI.

DIAPH2 SLC25A22 NF1 ITPR1

7.66e-0710424431240132
Pubmed

Zn2+ is essential for Ca2+ oscillations in mouse eggs.

TRPM7 ITPR1

1.37e-06324238099643
Pubmed

Cloning and chromosome mapping of human and chicken Iroquois (IRX) genes.

IRX2 IRX5

2.74e-06424211435706
Pubmed

Expression of two novel mouse Iroquois homeobox genes during neurogenesis.

IRX2 IRX5

4.56e-06524210704856
Pubmed

Iroquois genes influence proximo-distal morphogenesis during rat lung development.

IRX2 IRX5

4.56e-06524216299054
Pubmed

Comparison of Iroquois gene expression in limbs/fins of vertebrate embryos.

IRX2 IRX5

6.83e-06624220408909
Pubmed

Iroquois homeobox 3 regulates odontoblast proliferation and differentiation mediated by Wnt5a expression.

IRX2 IRX5

6.83e-06624236773339
Pubmed

Organization of mouse Iroquois homeobox genes in two clusters suggests a conserved regulation and function in vertebrate development.

IRX2 IRX5

6.83e-06624211042145
Pubmed

Regulated expression patterns of IRX-2, an Iroquois-class homeobox gene, in the human breast.

IRX2 IRX5

6.83e-06624210370142
Pubmed

The prepattern transcription factor Irx3 directs nephron segment identity.

IRX2 IRX5

9.56e-06724217875669
Pubmed

Identification of a novel mouse Iroquois homeobox gene, Irx5, and chromosomal localisation of all members of the mouse Iroquois gene family.

IRX2 IRX5

1.27e-05824210822268
Pubmed

In silico analysis identifies a putative cell-of-origin for BRAF fusion-positive cerebellar pilocytic astrocytoma.

IRX2 IRX5

1.27e-05824233206716
Pubmed

Sensitive nonradioactive detection of mRNA in tissue sections: novel application of the whole-mount in situ hybridization protocol.

IRX2 IRX5

1.27e-05824211118473
Pubmed

The Iroquois homeobox gene Irx2 is not essential for normal development of the heart and midbrain-hindbrain boundary in mice.

IRX2 IRX5

1.64e-05924214585979
Pubmed

Gene and cluster-specific expression of the Iroquois family members during mouse development.

IRX2 IRX5

1.64e-05924211520674
Pubmed

Presynaptically localized cyclic GMP-dependent protein kinase 1 is a key determinant of spinal synaptic potentiation and pain hypersensitivity.

TACR1 ITPR1

2.05e-051024222427743
Pubmed

Patterning the embryonic heart: identification of five mouse Iroquois homeobox genes in the developing heart.

IRX2 IRX5

2.50e-051124210926765
Pubmed

Control of TurboID-dependent biotinylation intensity in proximity ligation screens.

DIAPH2 CDS2 ITPR1

4.47e-0510024336966971
Pubmed

Identification of FMRP target mRNAs in the developmental brain: FMRP might coordinate Ras/MAPK, Wnt/β-catenin, and mTOR signaling during corticogenesis.

NF1 ITPR1

6.94e-051824233323119
Pubmed

Wnt/β-catenin promotes gastric fundus specification in mice and humans.

IRX2 IRX5

6.94e-051824228052057
Pubmed

The Iroquois homeobox gene, Irx5, is required for retinal cone bipolar cell development.

IRX2 IRX5

7.75e-051924216182275
Pubmed

Crucial role of vHNF1 in vertebrate hepatic specification.

IRX2 FGFR2

1.25e-042424218635606
Pubmed

Cardiomyopathy in Irx4-deficient mice is preceded by abnormal ventricular gene expression.

IRX2 IRX5

1.47e-042624211238910
Pubmed

Suppression of epithelial differentiation by Foxi3 is essential for molar crown patterning.

IRX2 IRX5

1.96e-043024226450968
Pubmed

Brn3a and Nurr1 mediate a gene regulatory pathway for habenula development.

IRX2 TACR1 IRX5

2.01e-0416624319906978
Pubmed

Tangential Intrahypothalamic Migration of the Mouse Ventral Premamillary Nucleus and Fgf8 Signaling.

FGFR2 IRX5

2.10e-043124234095148
Pubmed

Murine txk: a protein tyrosine kinase gene regulated by T cell activation.

AXL FGFR2

2.24e-04322427542761
Pubmed

Genome-wide association study of selenium concentrations.

IRX2 LHFPL2

2.68e-043524225343990
Pubmed

Maternal Transient Receptor Potential Vanilloid 6 (Trpv6) Is Involved In Offspring Bone Development.

TRPM7 ITPR1

3.16e-043824230786075
Pubmed

Epithelial inactivation of Yy1 abrogates lung branching morphogenesis.

IRX2 IRX5

4.05e-044324226329601
Pubmed

Mapping of unconventional myosins in mouse and human.

MYO9B NF1

5.05e-04482428884266
Pubmed

Shotgun sequencing of the human transcriptome with ORF expressed sequence tags.

NBEAL1 ABCA13 MYO9B ITPR1

5.18e-0455224410737800
Pubmed

Control of spinal motor neuron terminal differentiation through sustained Hoxc8 gene activity.

IRX2 IRX5

5.26e-044924235315772
InteractionSDC2 interactions

NBEAL1 FGFR2 NF1 ITPR1

2.31e-05143244int:SDC2
GeneFamilyTALE class homeoboxes and pseudogenes

IRX2 IRX5

3.00e-0426182526
GeneFamilyReceptor Tyrosine Kinases|CD molecules

AXL FGFR2

7.14e-0440182321
CoexpressionSHARMA_PILOCYTIC_ASTROCYTOMA_LOCATION_DN

IRX2 IRX5

1.68e-057242M19757
CoexpressionAtlasDevelopingKidney_e14.5 whole kidney - wildtype_emap-6674_k-means-cluster#3_top-relative-expression-ranked_1000

IRX2 TRPM7 NBEAL1 ITPR1

8.74e-06129224gudmap_developingKidney_e14.5 whole kidney - wildtype_1000_k3
ToppCellControl-Epithelial_alveolar-AT_1-AT1-AT2|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

IRX2 TACR1 FGFR2 IRX5 HTR1E

4.09e-08182245a95956ce4adccb34cc0c47ebfa1878ce4617904e
ToppCellControl-Epithelial_alveolar|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

IRX2 TACR1 FGFR2 IRX5 HTR1E

4.44e-081852453937e026add96a396122139daf8011cfbc60e75c
ToppCellPND14-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT2-AT2_prolif|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

PRPS2 IRX2 ABCA13 PPIP5K1

1.79e-06166244575c325db88d6909cdf0d5e664bd9098b89d4401
ToppCellPND10-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT2-AT2_prolif|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

PRPS2 IRX2 FGFR2 IRX5

1.97e-061702444ce81608111b9ee7cb974dad2c182f38db3dcd79
ToppCellControl-Epithelial_alveolar-AT_2-AT2|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

IRX2 FGFR2 IRX5 HTR1E

2.58e-06182244e97681a4102f3095d5d9e90ad70f1dc46e90983a
ToppCellControl-Epithelial_alveolar-AT_2|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

IRX2 FGFR2 IRX5 HTR1E

2.70e-0618424451e129b3fcc2df083eda05a3afe3717218b1e52b
ToppCellPND01-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT2-AT2_mature|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

PRPS2 IRX2 FGFR2 IRX5

2.76e-06185244fd51fef8c69e34c72017d8371ab0a0d7be5701f2
ToppCellPND01-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT2|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

PRPS2 IRX2 FGFR2 IRX5

2.76e-06185244bea26e369ae91006052b973cd89b4c49afa9e553
ToppCellControl-Epithelial_alveolar-AT_2-AT2_Progenitor|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

IRX2 FGFR2 IRX5 HTR1E

2.76e-061852448ca1374501eca01d8468130b74d50abfd4329fbe
ToppCellEpithelial-C_(AT2)|World / shred on cell class and cell subclass (v4)

PRPS2 IRX2 FGFR2 IRX5

2.82e-06186244b7b1763fc52b4485d843a4a6727055e6c95ebad3
ToppCellPND03-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT2|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

PRPS2 IRX2 FGFR2 IRX5

2.88e-06187244e176b5b051690f840f3b12c8f7c4cc10cbe2bbae
ToppCellPND03-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT2-AT2_mature|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

PRPS2 IRX2 FGFR2 IRX5

2.88e-061872446ab51e17a7782c2ae6394cad813dc3a2cde70c89
ToppCellfacs-Lung-nan-3m-Epithelial-Alveolar_Epithelial_Type_2|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PRPS2 IRX2 FGFR2 IRX5

3.13e-06191244c06bbad24e4897b2c3b5015e4de02411ebf75367
ToppCellfacs-Lung-nan-3m-Epithelial-type_II_pneumocyte|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PRPS2 IRX2 FGFR2 IRX5

3.13e-061912445f43f98cfe7a08d61ed55f34808fabfe47f1ac2e
ToppCellControl_saline-Epithelial_alveolar-AT_2-AT2|Control_saline / Treatment groups by lineage, cell group, cell type

IRX2 FGFR2 IRX5 HTR1E

3.54e-06197244f870a26f322668781e3d2832c5d9ef2c7c91011f
ToppCellParenchyma_COVID-19-Epithelial-TX-Club|Parenchyma_COVID-19 / Sample group, Lineage and Cell type

ABCA13 TACR1 FGFR2 IRX5

3.76e-0620024485f946dd3831acf3488c87efba96689cc2667c3a
ToppCellLung_Parenchyma-Severe-Epithelial-Epithelial-Club-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

ABCA13 TACR1 FGFR2 IRX5

3.76e-062002448a44a4f7ea9358f2194a490e79601c98ff7fdcb0
ToppCellLung_Parenchyma-Severe-Epithelial-Epithelial-Club|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)

ABCA13 TACR1 FGFR2 IRX5

3.76e-0620024430d428510c68da96c7c8cfd472f449ebb9631132
ToppCellLPS_only-Epithelial_alveolar-AT_1-Differentiating_AT2|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

IRX2 FGFR2 IRX5

1.96e-0598243ffe21b3681fdeaf4a8447bd2b13772d03cdd45aa
ToppCellLPS-IL1RA+antiTNF-Epithelial_alveolar-AT_2-AT1-AT2|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

IRX2 FGFR2 IRX5

4.78e-05132243c6bf0b4b9e33b517629faf4559a21d7ba720ee6a
ToppCellTCGA-Brain-Primary_Tumor-Low_Grade_Glioma-Oligodendroglioma-4|TCGA-Brain / Sample_Type by Project: Shred V9

HTR1E MCHR2 ITPR1

6.44e-05146243632f52780607c638b5d3dd3fb9251c719f162a35
ToppCellTCGA-Brain-Primary_Tumor-Low_Grade_Glioma-Oligoastrocytoma-4|TCGA-Brain / Sample_Type by Project: Shred V9

HTR1E MCHR2 ITPR1

6.85e-05149243ff472ad641efd655905e99a9a4cacd5245ab8854
ToppCellP03-Epithelial-epithelial_progenitor_cell-epi_progenitor|P03 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

IRX2 FGFR2 IRX5

7.12e-05151243fce04bce66411c21cd5d4d41375f26f1f50f3348
ToppCellThalamus-Neuronal-Excitatory-eN2(Slc17a7_Slc17a6)-Slc17a7-Tac2|Thalamus / BrainAtlas - Mouse McCarroll V32

IRX2 TACR1 IRX5

8.46e-05160243fe5fb0e7a79862f63529721f0a82f4f6d231d3ca
ToppCellThalamus-Neuronal-Excitatory-eN2(Slc17a7_Slc17a6)-Slc17a7|Thalamus / BrainAtlas - Mouse McCarroll V32

IRX2 TACR1 IRX5

8.46e-051602437d34159363d274019e14549d1186c629ce990691
ToppCellThalamus-Neuronal-Excitatory-eN2(Slc17a7_Slc17a6)|Thalamus / BrainAtlas - Mouse McCarroll V32

IRX2 TACR1 IRX5

8.61e-051612430605134a342d74ae81f33700d6ddfcd6e03aeb7b
ToppCellP07-Epithelial-epithelial_progenitor_cell-epithelial_progenitor_cell|P07 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

IRX2 FGFR2 IRX5

9.94e-0516924353e863de064d44e1d36e21fb3dbba37ae020f6e9
ToppCellP07-Epithelial-epithelial_progenitor_cell-epi_progenitor|P07 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

IRX2 FGFR2 IRX5

9.94e-051692431a47a4892a5e6a69555f5332308503526e5422a7
ToppCellP07-Epithelial-epithelial_progenitor_cell|P07 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

IRX2 FGFR2 IRX5

9.94e-05169243ec23caecbb0d969307e33e9df8499ddcd1420305
ToppCellP15-Epithelial-alveolar_epithelial_cell-type_II_pneumocyte|P15 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

IRX2 FGFR2 IRX5

1.01e-041702436c0619cbe2f01a6de18da0a137f92bda0cbdf075
ToppCellP03-Epithelial-alveolar_epithelial_cell-type_II_pneumocyte|P03 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

PRPS2 FGFR2 IRX5

1.01e-041702433fd37e9b377d6485cea1262c31a8507d18a78514
ToppCellP07-Epithelial|P07 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

IRX2 FGFR2 IRX5

1.07e-041732438b10087a917b825809d35a2b2b349c73a2782472
ToppCellP03-Epithelial-epithelial_progenitor_cell|P03 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

IRX2 FGFR2 IRX5

1.08e-0417424323c7fdfc73170cfc5cdee5bb7fbee0c8bbbbca07
ToppCellAdult-Epithelial-lung_goblet_cell-D231|Adult / Lineage, Cell type, age group and donor

TACR1 FGFR2 HTR1E

1.08e-041742437d2f802f493f19a068e097b2909a9000e2160266
ToppCellE17.5-Epithelial-alveolar_epithelial_cell-type_II_pneumocyte|E17.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

IRX2 FGFR2 IRX5

1.08e-0417424368914ec843f58ecff3e6412544a341daf8a01cac
ToppCellP07-Epithelial-alveolar_epithelial_cell|P07 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

IRX2 FGFR2 IRX5

1.08e-041742432739de68e0266054694f99807cfb1f07b6bbb371
ToppCellLPS-IL1RA+antiTNF-Epithelial_alveolar-AT_1-AT2_Progenitor|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

IRX2 FGFR2 IRX5

1.08e-04174243d0e3d15731de6c19c232e3aa492c39d8151cf4ed
ToppCellP28-Epithelial-alveolar_epithelial_cell-type_II_pneumocyte|P28 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

IRX2 FGFR2 IRX5

1.10e-041752438a4ed775ff973123dbcfe9c809959d11a62450c9
ToppCellP03-Epithelial-epithelial_progenitor_cell-epithelial_progenitor_cell|P03 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

IRX2 FGFR2 IRX5

1.10e-04175243a6d9ca35d3c4b4e3889d0a69b514f63ae630da6b
ToppCellrenal_cortex_nuclei-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Descending_Thin_Limb_Cell_Type_2|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

ABCA13 FGFR2 IRX5

1.10e-04175243284fdc7a9d303636a637041846850d19d114861a
ToppCell21-Trachea-Epithelial-Submucosal_gland|Trachea / Age, Tissue, Lineage and Cell class

IRX2 LHFPL2 FGFR2

1.16e-041782433e406e38eea0d38dc25edecf703c4c89ec6a28e0
ToppCellControl-Epithelial_alveolar-AT_1-AT1|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

IRX2 TACR1 IRX5

1.16e-041782431817bc520f3d23da8c0fa09bba50ae703a820cb1
ToppCellMid-temporal_gyrus_(MTG)|World / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types

DIAPH2 HTR1E MCHR2

1.16e-04178243ad187db4c40b9078d54dd915c143e0172b2f47b8
ToppCellPND07-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT2-AT2_prolif|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

IRX2 FGFR2 IRX5

1.18e-04179243bf012825e88626e59cd1deebf67c2cd269ce4829
ToppCelldroplet-Lung-3m-Epithelial-alveolar_epithelial-type_I_pneumocyte-type_1_alveolar_epithelial_cell|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

IRX2 FGFR2 IRX5

1.18e-04179243ca70a5518c5a5392e088c103e0cb44aa084f5332
ToppCellLPS-antiTNF-Epithelial_alveolar-AT_2-AT2_Progenitor|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

IRX2 FGFR2 IRX5

1.18e-041792437db6b97a1c4c7a163d5da4351ba36ac1785d9d7b
ToppCelldroplet-Lung-3m-Epithelial-alveolar_epithelial-type_I_pneumocyte|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

IRX2 FGFR2 IRX5

1.18e-04179243c451b074b04eb5d6c575c6abaedda579c6744bbf
ToppCelldroplet-Kidney-KIDNEY-30m-Epithelial-kidney_loop_of_Henle_ascending_limb_epithelial_cell|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PRPS2 IRX2 ABCA13

1.20e-041802430b653b1b653b40f3b8711d1312029a4a8a4961db
ToppCellLPS-antiTNF-Epithelial_alveolar-AT_2|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

IRX2 FGFR2 IRX5

1.20e-04180243b798a3fa2dd15b68aa4267f665559527043dcc07
ToppCellfacs-Lung-3m-Mesenchymal-fibroblast-adventitial_fibroblast-adventitial_fibroblast_l17|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

LHFPL2 AXL PCDH19

1.20e-0418024339ae8586efd91536e9ac6408d26de7e6d6237c41
ToppCellLPS_only-Epithelial_alveolar-AT_2-AT2_Progenitor|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

IRX2 FGFR2 IRX5

1.22e-041812430513b9e6673ff7bf8e72ba123ca3794b65d10170
ToppCellRA-01._Fibroblast_I|World / Chamber and Cluster_Paper

DIAPH2 LHFPL2 AXL

1.22e-041812432b6ddeb53a79a658e2ba78527ff48c155b20daa6
ToppCellP03-Epithelial|P03 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

IRX2 FGFR2 IRX5

1.22e-04181243de0466072f5b2ab8db3d9bab31e3205d1ff7cfb7
ToppCellrenal_cortex_nuclei-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

ABCA13 FGFR2 IRX5

1.22e-041812436a6bd8e020cb0929b6ecdcb55d467ad24fecfaf0
ToppCelldroplet-Lung-nan-3m-Epithelial|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

IRX2 FGFR2 IRX5

1.24e-04182243cfba75c1ffc39ac76db9e8e27394731942882b30
ToppCellLPS-antiTNF-Epithelial_alveolar-AT_2-AT2|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

IRX2 FGFR2 IRX5

1.24e-041822431e2149b222a3e9f64841aed45288a6f29394e7b0
ToppCelldroplet-Lung-nan-21m-Epithelial|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

IRX2 FGFR2 IRX5

1.24e-0418224340539ade8c3cd12b61f1cd0d493828e58282796b
ToppCelldroplet-Lung-nan-3m-Epithelial-type_II_pneumocyte|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

IRX2 FGFR2 IRX5

1.24e-041822437e7c7a26460d3003cdf0c0ffb96208a566aa09a7
ToppCelldroplet-Lung-nan-3m-Epithelial-Alveolar_Epithelial_Type_2|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

IRX2 FGFR2 IRX5

1.24e-04182243d836bfdc298ecd3558a973e393a329eb8bd59d79
ToppCellLPS-IL1RA+antiTNF-Epithelial_alveolar-AT_2|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

IRX2 FGFR2 IRX5

1.24e-0418224317ed11a7ea366dd3106400511d5e628d3f1a9c3e
ToppCellLPS_only-Epithelial_alveolar-AT_2-AT2|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

IRX2 FGFR2 IRX5

1.24e-04182243d1a1feef318062f25493355d7beee8e5fb0e4206
ToppCellLPS-antiTNF-Epithelial_alveolar-AT_1|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

IRX2 FGFR2 IRX5

1.26e-04183243ff6dde877659cde9daa3263db0932c9c9ef1adac
ToppCelldroplet-Kidney-nan-18m-Epithelial-kidney_loop_of_Henle_ascending_limb_epithelial_cell|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PRPS2 IRX2 ABCA13

1.26e-0418324303c7e69136d5a3b9c5b2c91733e9b1c791f45c49
ToppCellLPS-IL1RA+antiTNF-Epithelial_alveolar-AT_1-AT1-AT2|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

IRX2 FGFR2 IRX5

1.26e-0418324306ac66726ec53db810ebb90ec69cfdb903da53f6
ToppCellLPS-IL1RA+antiTNF-Epithelial_alveolar-AT_2-AT2|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

IRX2 FGFR2 IRX5

1.26e-041832435f2db95d44b7de68779de098892892af540fd431
ToppCellLPS-IL1RA+antiTNF-Epithelial_alveolar-AT_1-AT1|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

IRX2 TACR1 IRX5

1.26e-04183243274483009b309289e4cb84beedf6806430db6ff6
ToppCellLPS_only-Epithelial_alveolar-AT_2|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

IRX2 FGFR2 IRX5

1.26e-04183243e972432dd4d1bd31bb0982f4df3061e5e152658f
ToppCellrenal_cortex_nuclei-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Descending_Thin_Limb_Cell_Type_1|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

ABCA13 FGFR2 IRX5

1.26e-04183243cfae90c309622b5d499e62a3a8a8b9746478d28d
ToppCellfacs-Lung-EPCAM-18m-Epithelial-type_II_pneumocyte|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

IRX2 FGFR2 IRX5

1.28e-0418424304bd8ab5808fcfa923aa4d0edf6a7f88b7980122
ToppCellPrimary_Visual_cortex_(V1C)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_D_(IT_RORB_THEMIS_LINC00507)_3|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types

DIAPH2 PCDH19 MCHR2

1.28e-0418424330fddbc9696476d4d7f08e53f84ea994a4ed873a
ToppCellLPS-IL1RA-Epithelial_alveolar-AT_2-AT2|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

IRX2 FGFR2 IRX5

1.28e-04184243157a3d00165bb4a8c52c3e63ae57d9cf57500be7
ToppCellPrimary_Visual_cortex_(V1C)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_D_(IT_RORB_THEMIS_LINC00507)_3-Exc_L2-3_LINC00507_RPL9P17|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types

DIAPH2 PCDH19 MCHR2

1.28e-0418424396926efa220f03d0787322c9519bb9e8f64f74d0
ToppCellLPS-IL1RA+antiTNF-Epithelial_alveolar-AT_2-AT2_Progenitor|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

IRX2 FGFR2 IRX5

1.28e-04184243d0c212a8fbaad24597a84018442b25c61c17ea58
ToppCellLPS-antiTNF-Epithelial_alveolar-AT_1-AT2_Progenitor|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

IRX2 FGFR2 IRX5

1.28e-041842437cc5796557379c3d1db078c1aeda40659c6e401c
ToppCellPND07-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT2-AT2_mature|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

IRX2 FGFR2 IRX5

1.28e-0418424349705c8fec565b16216bdf48e83e27521f52d99a
ToppCellfacs-Lung-EPCAM-18m-Epithelial-Alveolar_Epithelial_Type_2|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

IRX2 FGFR2 IRX5

1.28e-04184243e727bf110cb6a91a655c1865b0e93e51e2f9dda3
ToppCelldroplet-Lung-nan-21m-Epithelial-type_II_pneumocyte|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

IRX2 FGFR2 IRX5

1.30e-041852430e7351cd6d6e6e8c29573042e168da50ee496cfc
ToppCellFetal_29-31_weeks-Mesenchymal-airway_smooth_muscle_cell-D088|Fetal_29-31_weeks / Lineage, Cell type, age group and donor

LHFPL2 MYO9B AXL

1.30e-04185243e58a009aaf342be019a909747b1895d5987d4daf
ToppCellLPS-IL1RA-Epithelial_alveolar-AT_2|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

IRX2 FGFR2 IRX5

1.30e-04185243fefaf227d89f680d6f3e91c4a94e26ab4d0dc6c3
ToppCelldroplet-Kidney-KIDNEY-1m-Epithelial-kidney_loop_of_Henle_ascending_limb_epithelial_cell|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PRPS2 ABCA13 FGFR2

1.30e-04185243af86e75096c1812ae27a78405355957ee8043d84
ToppCellLPS-antiTNF-Epithelial_alveolar-AT_1-AT1-AT2|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

IRX2 FGFR2 IRX5

1.30e-041852433bef59cc0aa939d2a7e52f0f6c61bc00528fe50b
ToppCellPND07-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT2|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

IRX2 FGFR2 IRX5

1.30e-041852432adb32096aa3473f8d417e5ce9e65264beca9b52
ToppCellLPS_only-Epithelial_alveolar-AT_1-AT1-AT2|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

IRX2 FGFR2 IRX5

1.30e-0418524368f428e169cfb77de970bdfdeea9b9f16f68d2ba
ToppCellControl-Epithelial_alveolar-AT_2-Differentiating_AT2|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

IRX2 FGFR2 HTR1E

1.30e-041852430d2add28ac1f4fa6de7699be009bf8391badaf4c
ToppCelldroplet-Lung-nan-21m-Epithelial-Alveolar_Epithelial_Type_2|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

IRX2 FGFR2 IRX5

1.30e-041852436938ac3cab536cf8a474eba441ce6dcdfcc43b53
ToppCellLPS-IL1RA-Epithelial_alveolar-AT_2-AT2_Progenitor|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

IRX2 FGFR2 IRX5

1.30e-04185243929b68b05b7686341329ac756d7df172cb4b810b
ToppCelldroplet-Fat-Scat-21m-Epithelial-epithelial_cell|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation

IRX2 FGFR2 IRX5

1.32e-04186243de88fafac51049ec1920695844d8ce8057940272
ToppCellfacs-Lung-EPCAM-24m-Epithelial-Alveolar_Epithelial_Type_2|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

IRX2 FGFR2 IRX5

1.32e-041862433c4994a1a7db06a61da8170e45e06aaef7896592
ToppCelldroplet-Fat-Scat-21m-Epithelial|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation

IRX2 FGFR2 IRX5

1.32e-0418624359710cff3f6f7c318ee2524b44c1a909f312c25e
ToppCellLPS_only-Epithelial_alveolar|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

IRX2 FGFR2 IRX5

1.32e-04186243e0a2ea4b46af742bc7c9b2072bb85e27d5c92712
ToppCellfacs-Lung-18m-Epithelial-alveolar_epithelial|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

IRX2 FGFR2 IRX5

1.32e-04186243c7214e762b3b48197fdd0b36a50a4de2550a888f
ToppCellfacs-Lung-EPCAM-24m-Epithelial-type_II_pneumocyte|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

IRX2 FGFR2 IRX5

1.32e-04186243a583d6fc0f1e729f6e9fd18d7b49d6eab9ca32b9
ToppCellLPS-IL1RA+antiTNF-Epithelial_alveolar-AT_2-Differentiating_AT2|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

IRX2 FGFR2 IRX5

1.32e-04186243e83718fabb057100835d3357df407f283d23fe16
ToppCelldroplet-Fat-Scat-21m-Epithelial-nan|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation

IRX2 FGFR2 IRX5

1.32e-041862437ff73ab8fed5da779ee9c7bd2e14a8363edb7509
ToppCellfacs-Lung-EPCAM-3m|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

IRX2 FGFR2 IRX5

1.32e-041862437c4eb769574f9f32753cea1cc38c711dabba88b9
ToppCellE17.5-Epithelial|E17.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

IRX2 FGFR2 IRX5

1.34e-04187243fdabe716ce67f2eede90548198cbe20bbf693570
ToppCellfacs-Lung-18m-Epithelial-alveolar_epithelial-type_II_pneumocyte-type_2_alveolar_epithelial_cell|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

IRX2 FGFR2 IRX5

1.34e-04187243a5318c888b334e8695f38971a7d100b93cdaf04b
ToppCellLPS-antiTNF-Epithelial_alveolar|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

IRX2 FGFR2 IRX5

1.34e-04187243201ff693e4756ee3e44762885b3a303a77eb535b
ToppCellPND01-03-samps-Epithelial-Alveolar_epithelial|PND01-03-samps / Age Group, Lineage, Cell class and subclass

IRX2 FGFR2 IRX5

1.34e-0418724323fe3cdd6cc9b067086a8392d104186d300298ea
ToppCellfacs-Trachea-nan-3m-Epithelial-basal_epithelial_cell_of_tracheobronchial_tree|Trachea / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

IRX2 FGFR2 IRX5

1.34e-04187243fe9fc21192ede2eea61f419d20ccda254569d0a6
DrugAC1L1F7R

DIAPH2 TACR1

6.38e-064242CID000053595
DrugNifuroxazide [965-52-6]; Down 200; 14.6uM; MCF7; HT_HG-U133A

CDS2 IRX5 HTR1E NF1

4.47e-051912442850_DN
DrugNorgestrel-(-)-D [797-63-7]; Up 200; 12.8uM; PC3; HT_HG-U133A

MYO9B TACR1 NF1 ITPR1

4.66e-051932443708_UP
DrugIsoetharine mesylate salt [7279-75-6]; Down 200; 12uM; MCF7; HT_HG-U133A

DIAPH2 MYO9B FGFR2 NF1

4.85e-051952443451_DN
DrugCetirizine dihydrochloride [83881-52-1]; Up 200; 8.6uM; PC3; HT_HG-U133A

DIAPH2 MYO9B FGFR2 HTR1E

4.95e-051962444231_UP
DrugHeliotrine [303-33-3]; Down 200; 12.8uM; MCF7; HT_HG-U133A

MYO9B FGFR2 HTR1E NF1

4.95e-051962444739_DN
DrugHeliotrine [303-33-3]; Up 200; 12.8uM; PC3; HT_HG-U133A

DIAPH2 MYO9B IRX5 NF1

5.04e-051972443717_UP
DrugNeomycin sulfate [1405-10-3]; Up 200; 4.2uM; MCF7; HT_HG-U133A

DIAPH2 TACR1 FGFR2 NF1

5.14e-051982447221_UP
DrugCalcium

TRPM7 TACR1 PCDH19 NF1 ITPR1

1.41e-04493245ctd:D002118
Drugnorcamphor

DIAPH2 IRX2

2.66e-0423242CID000010345
Drugestradiol-17 beta-benzoate

TACR1 FGFR2

2.90e-0424242ctd:C010452
DrugA19413

DIAPH2 TACR1 FGFR2

3.45e-04131243CID000005307
Drug3-(4'-hydroxy-3'-adamantylbiphenyl-4-yl)acrylic acid

PRPS2 IRX2 MYO9B AXL NF1

3.70e-04607245ctd:C472791
DrugSuramin

TACR1 FGFR2

4.86e-0431242ctd:D013498
DrugSureCN1562346

AXL TACR1

5.51e-0433242CID011646228
DrugPx A

DIAPH2 NF1

5.51e-0433242CID003330140
Drugnitrobenzyl-DOTA

COG1 FGFR2

6.20e-0435242CID000129949
Drugmag-fura-2

TRPM7 ITPR1

6.93e-0437242CID000123839
DrugAC1L9GQC

DIAPH2 SLC25A22

6.93e-0437242CID000444689
DrugAC1L1BDQ

TRPM7 MCHR2 ITPR1

7.76e-04173243CID000001394
DrugTetrahydrozoline hydrochloride [522-48-5]; Up 200; 16.8uM; HL60; HT_HG-U133A

DIAPH2 AXL TACR1

8.02e-041752432507_UP
Drug2-methyl-5-HT

TACR1 HTR1E

8.11e-0440242CID000001574
DrugAC1L9GJJ

NF1 ITPR1

8.11e-0440242CID000444570
DrugAC1L9K36

MYO9B TACR1

8.52e-0441242CID000446779
Drugprochlorperazine dimaleate salt; Up 200; 10uM; HL60; HT_HG-U133A

LHFPL2 MYO9B AXL

8.84e-041812432675_UP
DrugCiclopirox ethanolamine [41621-49-2]; Down 200; 15uM; MCF7; HT_HG-U133A

FGFR2 IRX5 HTR1E

8.99e-041822433317_DN
Drug17-AAG; Up 200; 1uM; MCF7; HT_HG-U133A

MYO9B FGFR2 HTR1E

9.13e-041832436985_UP
DrugHycanthone [3105-97-3]; Down 200; 11.2uM; HL60; HG-U133A

DIAPH2 NF1 ITPR1

9.72e-041872431614_DN
Drugradicicol; Up 200; 0.1uM; MCF7; HT_HG-U133A_EA

DIAPH2 MYO9B FGFR2

9.72e-04187243953_UP
DrugHexetidine [141-94-6]; Up 200; 11.8uM; MCF7; HT_HG-U133A

MYO9B TACR1 NF1

9.72e-041872435420_UP
DrugProtriptyline hydrochloride [1225-55-4]; Up 200; 13.4uM; MCF7; HT_HG-U133A

MROH9 NF1 ITPR1

9.72e-041872435438_UP
DrugQuercetine dihydrate [6151-25-3]; Up 200; 11.8uM; HL60; HT_HG-U133A

LHFPL2 AXL FGFR2

1.00e-031892432499_UP
Drugwortmannin; Down 200; 1uM; MCF7; HT_HG-U133A_EA

DIAPH2 FGFR2 HTR1E

1.00e-03189243869_DN
DrugAlprostadil [745-65-3]; Up 200; 11.2uM; PC3; HT_HG-U133A

DIAPH2 NF1 ITPR1

1.00e-031892434099_UP
Drug5253409; Up 200; 17uM; MCF7; HT_HG-U133A_EA

MYO9B FGFR2 NF1

1.02e-03190243961_UP
DrugTrichostatin A, from Streptomyces sp.; Up 200; 0.1uM; HL60; HT_HG-U133A

LHFPL2 FGFR2 NF1

1.02e-031902432375_UP
Drugradicicol, diheterospora chlamydosporia; Up 200; 0.1uM; MCF7; HT_HG-U133A

FGFR2 NF1 ITPR1

1.02e-031902436979_UP
Drug17-DMAG; Up 200; 0.1uM; PC3; HT_HG-U133A

TACR1 HTR1E NF1

1.02e-031902434437_UP
Drug1yej

MCHR2 NF1

1.03e-0345242CID000449245
DrugIsoetharine mesylate salt [7279-75-6]; Up 200; 12uM; PC3; HT_HG-U133A

TACR1 NF1 ITPR1

1.05e-031922435812_UP
DrugHexetidine [141-94-6]; Down 200; 11.8uM; MCF7; HT_HG-U133A

DIAPH2 FGFR2 NF1

1.05e-031922433318_DN
DrugNaltrexone hydrochloride dihydrate [16676-29-2]; Down 200; 9.6uM; HL60; HG-U133A

SLC25A22 MYO9B NF1

1.06e-031932431363_DN
DrugDeltaline [6836-11-9]; Up 200; 7.8uM; PC3; HT_HG-U133A

MYO9B FGFR2 HTR1E

1.06e-031932434306_UP
DrugCalycanthine [595-05-1]; Up 200; 11.6uM; MCF7; HT_HG-U133A

FGFR2 NF1 ITPR1

1.06e-031932432764_UP
DrugAC1OAGKW

CDS2 HTR1E ITPR1

1.06e-03193243CID006857413
DrugAnabasine [494-52-0]; Down 200; 24.6uM; MCF7; HT_HG-U133A

DIAPH2 FGFR2 NF1

1.08e-031942436774_DN
Druglomustine; Down 200; 100uM; MCF7; HT_HG-U133A

MYO9B FGFR2 IRX5

1.08e-031942437089_DN
DrugFurazolidone [67-45-8]; Down 200; 17.8uM; MCF7; HT_HG-U133A

MYO9B NF1 ITPR1

1.08e-031942434178_DN
DrugColchicine [64-86-8]; Up 200; 10uM; MCF7; HT_HG-U133A

MYO9B NF1 ITPR1

1.08e-031942433213_UP
Drug0179445-0000 [211246-22-9]; Down 200; 1uM; MCF7; HT_HG-U133A

SLC25A22 HTR1E NF1

1.08e-031942434758_DN
DrugSpiramycin [8025-81-8]; Down 200; 4.8uM; MCF7; HT_HG-U133A

DIAPH2 SLC25A22 NF1

1.08e-031942433419_DN
DrugFlumethasone [2135-17-3]; Up 200; 9.8uM; MCF7; HT_HG-U133A

TACR1 NF1 ITPR1

1.08e-031942433610_UP
Drugradicicol; Down 200; 0.1uM; PC3; HT_HG-U133A

MYO9B FGFR2 HTR1E

1.08e-031942435952_DN
DrugMephenytoin [50-12-4]; Down 200; 18.4uM; MCF7; HT_HG-U133A

MYO9B NF1 ITPR1

1.10e-031952433580_DN
DrugTriflusal [322-79-2]; Down 200; 16.2uM; MCF7; HT_HG-U133A

MYO9B HTR1E ITPR1

1.10e-031952432867_DN
DrugFlecainide acetate [54143-56-5]; Up 200; 8.4uM; PC3; HT_HG-U133A

TACR1 FGFR2 NF1

1.10e-031952434318_UP
Drug(1-[(4-Chlorophenyl)phenyl-methyl]-4-methylpiperazine) [1620-21-9]; Down 200; 11.8uM; MCF7; HT_HG-U133A

MYO9B FGFR2 HTR1E

1.10e-031952433893_DN
DrugPipenzolate bromide [125-51-9]; Down 200; 9.2uM; MCF7; HT_HG-U133A

SLC25A22 MYO9B NF1

1.10e-031952436821_DN
DrugAminopurine, 6-benzyl [1214-39-7]; Down 200; 17.8uM; MCF7; HT_HG-U133A

DIAPH2 NF1 ITPR1

1.10e-031952432313_DN
DrugFlupentixol dihydrochloride cis-(Z) [2413-38-9]; Up 200; 7.8uM; MCF7; HT_HG-U133A

FGFR2 NF1 ITPR1

1.10e-031952432643_UP
DrugBiperiden hydrochloride [1235-82-1]; Down 200; 11.4uM; HL60; HT_HG-U133A

LHFPL2 CDS2 NF1

1.10e-031952432460_DN
DrugTiclopidine hydrochloride [53885-35-1]; Down 200; 13.4uM; MCF7; HT_HG-U133A

MYO9B NF1 ITPR1

1.10e-031952434155_DN
DrugHydralazine hydrochloride [304-20-1]; Down 200; 20.4uM; MCF7; HT_HG-U133A

DIAPH2 FGFR2 ITPR1

1.10e-031952432311_DN
DrugAmiodarone hydrochloride [19774-82-4]; Down 200; 5.8uM; MCF7; HT_HG-U133A

MYO9B NF1 ITPR1

1.10e-031952435618_DN
Drug(+) -Levobunolol hydrochloride [47141-41-3]; Down 200; 12.2uM; MCF7; HT_HG-U133A

FGFR2 HTR1E ITPR1

1.10e-031952434980_DN
DrugGlycocholic acid [475-31-0]; Down 200; 8.6uM; MCF7; HT_HG-U133A

FGFR2 HTR1E NF1

1.10e-031952433315_DN
DrugAmitryptiline hydrochloride [549-18-8]; Up 200; 12.8uM; MCF7; HT_HG-U133A

HTR1E NF1 ITPR1

1.10e-031952431701_UP
DrugProbucol [23288-49-5]; Down 200; 7.8uM; MCF7; HT_HG-U133A

MYO9B HTR1E NF1

1.10e-031952435626_DN
DrugRepaglinide [135062-02-1]; Down 200; 8.8uM; HL60; HT_HG-U133A

MYO9B CDS2 NF1

1.10e-031952436135_DN
DrugHomatropine hydrobromide (R,S) [51-56-9]; Up 200; 11.2uM; MCF7; HT_HG-U133A

FGFR2 NF1 ITPR1

1.11e-031962431684_UP
Drug(d,l)-Tetrahydroberberine [522-97-4]; Down 200; 11.8uM; MCF7; HT_HG-U133A

MYO9B NF1 ITPR1

1.11e-031962432818_DN
DrugMethylhydantoin-5-(D) [55147-68-7]; Down 200; 35uM; MCF7; HT_HG-U133A

DIAPH2 MYO9B NF1

1.11e-031962433333_DN
DrugDyclonine hydrochloride [536-43-6]; Down 200; 12.2uM; MCF7; HT_HG-U133A

SLC25A22 FGFR2 NF1

1.11e-031962437022_DN
DrugGuaifenesin [93-14-1]; Up 200; 20.2uM; HL60; HT_HG-U133A

LHFPL2 FGFR2 HTR1E

1.11e-031962432569_UP
Drugrosiglitazone; Down 200; 10uM; MCF7; HT_HG-U133A

MYO9B HTR1E ITPR1

1.11e-031962435593_DN
DrugBrompheniramine maleate [980-71-2]; Down 200; 9.2uM; MCF7; HT_HG-U133A

DIAPH2 MYO9B HTR1E

1.11e-031962433271_DN
DrugLovastatin [75330-75-5]; Up 200; 9.8uM; HL60; HT_HG-U133A

FGFR2 HTR1E NF1

1.11e-031962432494_UP
DrugKhellin [82-02-0]; Down 200; 15.4uM; MCF7; HT_HG-U133A

HTR1E NF1 ITPR1

1.11e-031962434987_DN
DrugGBR 12909 dihydrochloride [67469-78-7]; Up 200; 7.6uM; HL60; HG-U133A

SLC25A22 AXL CDS2

1.11e-031962431625_UP
Diseaseserum gamma-glutamyl transferase measurement

TRPM7 LHFPL2 L3MBTL3 AXL FGFR2 NF1 ITPR1

5.83e-06914247EFO_0004532
DiseaseSchwannomatosis, Plexiform

AXL NF1

6.33e-065242C0751374
Diseasehip circumference

IRX2 TRPM7 L3MBTL3 TACR1 NF1

6.80e-06338245EFO_0005093
DiseaseNeurilemmoma

AXL NF1

9.49e-066242C0027809
DiseaseBipolar Disorder

ABCA13 TACR1 FGFR2 MCHR2 ITPR1

3.56e-05477245C0005586
DiseaseOvarian Serous Adenocarcinoma

TRPM7 FGFR2

1.59e-0423242C1335177
Diseaseattention deficit hyperactivity disorder (implicated_via_orthology)

TACR1 NF1

2.37e-0428242DOID:1094 (implicated_via_orthology)
Diseasetransient cerebral ischemia (biomarker_via_orthology)

FGFR2 NF1 ITPR1

2.76e-04157243DOID:224 (biomarker_via_orthology)
DiseaseAdenoma

TRPM7 NF1

3.93e-0436242C0001430
DiseaseAdenoma, Microcystic

TRPM7 NF1

3.93e-0436242C0205648
DiseaseAdenoma, Monomorphic

TRPM7 NF1

3.93e-0436242C0205649
DiseaseAdenoma, Basal Cell

TRPM7 NF1

3.93e-0436242C0205646
DiseaseFollicular adenoma

TRPM7 NF1

3.93e-0436242C0205647
DiseasePapillary adenoma

TRPM7 NF1

3.93e-0436242C0205650
DiseaseAdenoma, Trabecular

TRPM7 NF1

3.93e-0436242C0205651
Diseasespleen volume

L3MBTL3 MYO9B

5.61e-0443242EFO_0600047
DiseaseGastric Adenocarcinoma

TRPM7 AXL

6.14e-0445242C0278701
Diseaseaspartate aminotransferase measurement

TRPM7 L3MBTL3 AXL NF1 ITPR1

6.98e-04904245EFO_0004736
Diseasetotal cholesterol measurement, triglyceride measurement, low density lipoprotein cholesterol measurement, high density lipoprotein cholesterol measurement

L3MBTL3 NF1

7.28e-0449242EFO_0004530, EFO_0004574, EFO_0004611, EFO_0004612
Diseaseretinal vasculature measurement

LHFPL2 NBEAL1 FGFR2 ITPR1

7.49e-04517244EFO_0010554

Protein segments in the cluster

PeptideGeneStartEntry
EKMLICMTLVVITTL

HTR1E

21

P28566
PMVLMIIVMCVQIKC

CDS2

91

O95674
QKVKMMVVRVLTIVA

ABCA13

2931

Q86UQ4
MMTEIVKILSAICIV

DIAPH2

271

O60879
IIFKIMEQMLKCTNV

NBEAL1

1156

Q6ZS30
KIMLAIITKMTLTQV

IRX5

146

P78411
LLMTQTDIVKIMSIK

L3MBTL3

741

Q96JM7
MSSSMEICVIKVEIK

PCDH19

106

Q8TAB3
MVVTVILCRMKNTTK

FGFR2

391

P21802
CIKVLQTLREMMTKD

ITPR1

1681

Q14643
MTIMNKKVCVLLVVT

OR4K17

136

Q8NGC6
CQVIVTTPMEMLKIQ

SLC25A22

116

Q9H936
LVSVFTMCVQSIMKK

LHFPL2

116

Q6ZUX7
MKDVMLQVITLLTCT

MROH9

311

Q5TGP6
EKIMLAIITKMTLTQ

IRX2

146

Q9BZI1
VMKLTKMVLVLVVVF

MCHR2

246

Q969V1
KVTLQEMLKSCMVQV

COG1

766

Q8WTW3
SAKRKVVKMMIVVVC

TACR1

241

P25103
MKHCTKIQVIDISMI

PRPS2

281

P11908
ILKVAVKTMKIAICT

AXL

561

P30530
IKTKLCQLVEVMMAR

NF1

1011

P21359
QTLMECMKRKELITV

TRPM7

366

Q96QT4
MLTAMEKLVARKVCV

PPIP5K1

296

Q6PFW1
SMKDVLKITTCVEML

MYO9B

1866

Q13459
LKITTCVEMLIKEQM

MYO9B

1871

Q13459